DDInter923 DDInter150
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Tioguanine {u} (Compound) resembles {v} (Compound) Adenine
Adenine {u} (Compound) resembles {v} (Compound) Azathioprine
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Tioguanine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is bound by {v} (Compound) Azathioprine
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Tioguanine {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) upregulates {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Betamethasone
Betamethasone {u} (Compound) upregulates {v} (Gene) MRPL12
MRPL12 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Infliximab may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine (Compound) resembles Adenine (Compound) and Adenine (Compound) resembles Azathioprine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is bound by Azathioprine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Azathioprine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Azathioprine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) upregulates GTPBP8 (Gene) and GTPBP8 (Gene) is upregulated by Azathioprine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is downregulated by Azathioprine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Azathioprine (Compound)
Infliximab may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone (Compound) upregulates MRPL12 (Gene) and MRPL12 (Gene) is downregulated by Azathioprine (Compound)